Brexit: EC proposes legislative amendments for the relocation of the EMA and the EBA from London
The European Commission recently made two legislative proposals to amend the founding Regulations of the European Medicines Agency (EMA) and the European Banking Authority (EBA).
This follows last week's agreement in the margins of the General Affairs Council (Article 50 format) to move the EMA and the EBA from London to Amsterdam and Paris, respectively.
The Commission is acting swiftly in order to provide legal certainty and clarity, ensuring that both Agencies can continue to function smoothly and without disruption beyond March 2019. Under the ordinary legislative procedure, the co-legislators (the European Parliament and the Council) are expected to give priority to the handling of these legislative proposals. These proposals are strictly limited to confirming the new seats of the Agencies in the two founding Regulations.
The relocation of these two Agencies is a direct consequence of the United Kingdom's decision to leave the European Union, as notified to the European Council on 29 March 2017. The decision to relocate both Agencies was for the governments of the 27 Member States to take. It does not form part of the Brexit negotiations.
For More Information
- Margaritis SCHINAS (+ 32 2 296 05 24)
- Mina ANDREEVA (+32 2 299 13 82)
- Daniel FERRIE (+32 2 298 65 00)
Latest News from
Council and Parliament reach provisional agreement on new EU waste rules18/12/2017 16:25:00
The Estonian presidency hasreached a provisional agreement with representatives of the European Parliament on all four legislative proposals of the waste package.
Europe – the continent of solidarity18/12/2017 15:25:00
Statement on the occasion of International Migrant Day
European Council meetings of 14 and 15 December 201718/12/2017 14:10:00
Remarks by President Jean-Claude Juncker following the European Council meetings of 14 and 15 December 2017
Modified-release paracetamol-containing products to be suspended from EU market18/12/2017 13:15:00
The CMDh has endorsed, by majority, a European Medicines Agency recommendation to suspend marketing of modified- or prolonged-release products containing paracetamol (designed to release paracetamol slowly over a longer period than the usual immediate-release products).